Table 2.
Association between NRH:quinone oxidoreductase 2 (NQO2) tri-allelic polymorphism and breast cancer risk in the whole study population.
| Control (N = 1,655, %)* | Case (N = 1,143, %)* | p ζ | Dominant model OR (95% CI)¶,Δ | p | Recessive model OR (95% CI)¶,Δ | p | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Genotype | I-29/I-29 | 1,024 | 61.9 | 778 | 68.1 | 0.003 | 1.31 (1.12–1.54) | 0.001 | 1.22 (0.80–1.85) | 0.36 |
| I-29/D | 568 | 34.3 | 329 | 28.8 | ||||||
| D/D | 63 | 3.8 | 36 | 3.1 | ||||||
| Allele | I-29 | 2,616 | 79.0 | 1885 | 82.5 | 0.0015 | ||||
| D | 694 | 21.0 | 401 | 17.5 | ||||||
*
individuals with the I-16 allele were excluded from the analysis.
ζ
unadjusted p-value of two-sided χ2 test.
¶
odds ratio (OR) and 95% CI calculated by logistic regression, adjusted for age, age at menarche, menopausal status, and body mass index.
Δ
For the model, homozygotes for the major allele (1/1), heterozygotes (1/2), and homozygotes for the rare allele (2/2) are coded as a continuous numeric variable for genotype (i.e., 0, 1, and 2). The dominant model is defined as contrasting genotypic groups 1/1 vs. (1/2 + 2/2), and the recessive model is defined as contrasting genotypic groups 2/2 vs. (1/1 + 1/2).